Page last updated: 2024-12-08

trimethaphan camsylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trimethaphan camsylate : The (S)-camphorsulfonate salt of trimethaphan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441310
CHEMBL ID1245
SCHEMBL ID122467
MeSH IDM0068796

Synonyms (14)

Synonym
2-oxo-1,3-bis(phenylmethyl)decahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium (7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonate
trimethaphan camsylate
trimethaphan 10-camphorsulfonate
D00612
trimetaphan camsilate (jan/inn)
68-91-7
trimetaphan camsylate
arfonad (tn)
CHEMBL1245
SCHEMBL122467
DTXSID3023710
3,5-dibenzyl-8-thionia-3,5-diazatricyclo[6.3.0.02,6]undecan-4-one;(7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl)methanesulfonate
Q7842197
trimetaphan (rs)-camsilate

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" There was a strict dose-response relationship between duration of ischemia and mortality."( Forebrain ischemia in the rat. Relation between duration of ischemia, use of adjunctive ganglionic blockade and long-term recovery.
Arfors, KE; Gerdin, B; Grøgaard, B,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID52521Effective concentration required to give 50% cell kill with 4 J/cm**2 of light.(Dark and light induced toxicity towards murine colon carcinoma cell line(COLO-26 cells))2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. II. Effects of core heteroatoms and meso-substituents on biological activity.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990109 (83.85)18.7374
1990's12 (9.23)18.2507
2000's5 (3.85)29.6817
2010's4 (3.08)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.64 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (5.30%)5.53%
Reviews4 (2.65%)6.00%
Case Studies1 (0.66%)4.05%
Observational0 (0.00%)0.25%
Other138 (91.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 [NCT02726711]Phase 12 participants (Actual)Interventional2016-04-30Active, not recruiting
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension [NCT02245230]Phase 134 participants (Anticipated)Interventional2015-01-31Active, not recruiting
The Autonomic Nervous System, Nitric Oxide and TPA Interactions [NCT01137253]Phase 121 participants (Actual)Interventional2010-06-30Completed
Obesity, Hypertension in African American Women, Neuro-metabolic Mechanism [NCT01122407]Phase 134 participants (Actual)Interventional2010-01-31Completed
Autonomic Nervous System and Chronic Fatigue Syndrome [NCT00580619]Phase 1170 participants (Actual)Interventional2007-04-30Completed
The Autonomic Nervous System and Obesity [NCT00179023]Phase 1128 participants (Actual)Interventional2003-04-30Completed
Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension [NCT02425566]Phase 112 participants (Anticipated)Interventional2015-04-30Active, not recruiting
Cardiovascular Regulation: Autonomic/Metabolic Mechanisms PO1 HL56693, Project 4: Cardiovascular Regulation: Autonomic/Metabolic Mechanisms [NCT00178919]112 participants (Actual)Interventional2002-08-31Completed
Acute Sympathetic Blockade and Endogenous Glucose Production [NCT03028571]Phase 10 participants (Actual)Interventional2017-04-17Withdrawn(stopped due to The investigators decided not to perform the study. No participants have been enrolled.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00178919 (2) [back to overview]Change in Systolic Blood Pressure
NCT00178919 (2) [back to overview]Systolic Blood Pressure in Response to Systemic Nitric Oxide Inhibition

Change in Systolic Blood Pressure

L-NMMA (nitric oxide synthase inhibitor) was infused intravenously at different doses for 15 minutes each, after blocking the autonomic nervous system with trimethaphan. The change in systolic blood pressure at the end of the highest tolerated dose is the main outcome. Trimethaphan infused intravenously was used to produce transient blockade of the autonomic nervous system to allow for a full response to nitric oxide inhibition (in the absence of the baroreflex. (NCT00178919)
Timeframe: At the end of the highest tolerated dose of IV infusion of L-NMMA

Interventionmm Hg (Mean)
Autonomic Failure Patients43
Hypertensives and Controls21

[back to top]

Systolic Blood Pressure in Response to Systemic Nitric Oxide Inhibition

Systolic blood pressure at the highest tolerated dose of IV infusion of L-NMMA during autonomic nervous system blockade with trimethaphan. Trimethaphan, infused intravenously was used to produce transient blockade of the autonomic nervous system to allow for a full response to nitric oxide inhibition (in the absence of the baroreflex. (NCT00178919)
Timeframe: End of 15 minutes of infusion of L-NMMA at the highest tolerated dose

Interventionmm Hg (Mean)
Autonomic Failure Patients152
Hypertensives and Controls136

[back to top]